Reduce anemia and transfusion dependency

Myelofibrosis (MF) is a rare clonal disease of pluripotent hematopoietic stem and progenitor cells. There have been significant advances in the treatment options for MF in recent years, but anemia remains a major challenge in disease management. This is also reflected in the results of a survey study published in 2024, which was presented at this year’s congress of the European Association of Hematology (EHA).